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PURPOSE. The Zinc Finger Protein 469 (ZNF469) gene has been proposed as a candidate gene
for keratoconus due to the association of an upstream polymorphism (rs9938149) with the
disease in two independent studies, and the role of the gene in the autosomal recessive
disease Brittle Cornea Syndrome. Coding variants in ZNF469 have been assessed for
association with keratoconus in several small studies, with conﬂicting results. We assessed
rare, potentially pathogenic variants in ZNF469 for enrichment in keratoconus patients in a
cohort larger than all previous studies combined.
METHODS. ZNF469 was sequenced in 385 Australian keratoconus patients of European
descent, 346 population controls, and 230 ethnically matched screened controls by either
whole exome sequencing or targeted gene sequencing. The frequency of rare and very rare
potentially pathogenic variants was compared between cases and controls using v2 or Fisher’s
exact tests and further explored using a gene based test (Sequence Kernel Association Test
[SKAT]), weighting on the rarity of variants.
RESULTS. A total of 49 rare, including 33 very rare, potentially pathogenic variants were
identiﬁed across all groups. No enrichment of rare or very rare potentially pathogenic variants
in ZNF469was observed in our cases compared to the control groups following analysis using
v2 or Fisher’s exact tests. This ﬁnding was further supported by the SKAT results, which found
no signiﬁcant difference in the frequency of variants predicted to be damaging between cases
and either control group (P ¼ 0.06).
CONCLUSIONS. Rare variants in ZNF469 do not contribute to keratoconus susceptibility and do
not account for the association at rs9938149.
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Keratoconus (OMIM 148300) is a complex disease charac-terized by the progressive thinning and protrusion of the
cornea. This causes high myopia and irregular astigmatism and
can severely affect vision and quality of life.1 Standard
treatments such as hard contact lenses are difﬁcult to manage,
are often painful for the patient, and corneal transplantation is
ultimately required in a large proportion of patients.2,3
Keratoconus has an incidence of 1 in 50,0002,4 and usually
develops between puberty and early adulthood. The prevalence
is reported to be between 17 and 229 per 100,000, and varies
greatly between studies, ethnicities, and geographical loca-
tions.2,5–10 In Caucasians, the prevalence is estimated at 54.5
per 100,000.2 There is strong evidence for the role of genetic
risk factors in keratoconus susceptibility; however, largely the
functional variants and genes involved in disease development
and progression have not been elucidated.10–12 Identifying
genetic factors underlying keratoconus susceptibility would
improve our understanding of the disease pathogenesis and aid
the development of novel, nonsurgical treatments, which
would ultimately improve the quality of life for patients.
As keratoconus progresses, the cornea thins and bulges
forward forming a cone shape. Therefore, it has been
hypothesized that genes involved in central corneal thickness
(CCT) may play a role in the etiology of keratoconus. Under this
hypothesis, a genome-wide association study (GWAS) by Lu et
al.13 for CCT assessed genome-wide signiﬁcant single nucleo-
tide polymorphisms (SNPs) in a large cohort of keratoconus
patients.13 A SNP upstream of the Zinc Finger Protein 469
(ZNF469) gene, rs9938149, showed a suggestive association
with keratoconus; however, the genotype associated with a
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thinner cornea was associated with decreased keratoconus
risk.13 This ﬁnding was replicated in an independent cohort
showing the same direction of association,14 indicating that the
association is likely to be real, if nonintuitive. As ZNF469 is the
closest gene to this SNP, it has been hypothesized that genetic
variation within the gene may account for the association at
rs9938149 as well as contribute to CCT and keratoconus
susceptibility.
The potential role of ZNF469 in keratoconus pathogenesis
is further supported by the role of this gene in Brittle Cornea
Syndrome type 1 (BCS1, OMIM 229200). BCS1 is a rare,
autosomal recessive connective tissue disorder, caused by
biallelic loss-of-function variants in ZNF469. A key feature of
this syndrome is extremely thin corneas that are prone to
spontaneous rupture. This suggests that ZNF469 is important
for the structural integrity of the cornea.
As an appealing candidate, coding variants in ZNF469 in
keratoconus have since been investigated. Two of these studies
reported an association of potentially pathogenic variants in
ZNF469 with keratoconus, while two showed no association
with disease.15–18 Lechner et al.17 assessed 112 cases and 96
local controls in a combined United Kingdom and Swiss cohort
while Vincent et al.18 examined a largely Polynesian cohort
involving 43 cases and 46 controls from New Zealand. Both of
these studies concluded that rare potentially pathogenic
variants in ZNF469 were enriched in keratoconus. Conversely,
work by Karolak and colleagues16 did not identify any
difference in the frequency of nonsynonymous variants
between 42 cases, 49 individuals with high myopia, and 268
controls without eye disease in a Polish cohort. Furthermore, a
study by Davidson et al.15 showed that uncommon and rare
potentially pathogenic variants in 11 families with keratoconus
(six of Middle Eastern heritage and ﬁve of mixed ethnicities)
did not segregate with disease. This study also examined four
heterozygous carriers of nonsense or frame-shift variants in
ZNF469, and found no evidence of keratoconus.15
The potential involvement of ZNF469 in keratoconus
remains unclear and further assessment of this candidate gene
is required. It is likely that the contrasting ﬁndings from
previous studies are due to their small sample sizes. To address
this, our study examined the frequency of rare potentially
pathogenic variants in ZNF469 in 385 keratoconus cases
compared to ethnically matched controls. By assessing more
cases than all previous studies combined, the present study
allows for a more comprehensive analysis of the potential
contribution of rare variants in ZNF469 to keratoconus risk.
METHODS
All investigations adhered to the principles of the Declaration
of Helsinki and were approved by the Southern Adelaide
Clinical Human Research Committee and the Human Research
Ethics committee Tasmania. All participants gave written
informed consent.
Case Cohort
Australian keratoconus patients of European descent were
referred by treating optometrists and ophthalmologists and
recruited through the Flinders Eye Clinic (Adelaide, Australia)
and optometry clinics in Adelaide and Melbourne. Additionally,
members of Keratoconus Australia were recruited from across
Australia via mail. Clinical examinations were performed by an
experienced ophthalmologist. Individuals were diagnosed with
keratoconus if they had videokeratographic features of
keratoconus or any of the following clinical signs: conical
corneal protrusion, central or paracentral stromal thinning or
other distinctive features such as Fleischer’s ring, Vogt’s striae,
epithelial or subepithelial scarring, or oil droplet sign and/or
scissoring of the retinoscopic reﬂex. In addition, individuals
with a history of corneal transplantation for keratoconus were
also classiﬁed as cases. Peripheral blood was donated by
patients and DNA was extracted using the QiaAmp DNA Maxi
Kit (Qiagen, Hilden, Germany).
Control Cohorts
Two Australian control cohorts of European descent were used
in this study. The ﬁrst, the ‘‘population controls’’, were an
ethnically matched cohort from the Anglo-Australasian Osteo-
porosis Genetics Consortium (n ¼ 346). These individuals are
all female with moderately high or low bone mineral density
measurements (1.5<jBMDj<4.0), but were not examined for
eye disease. The second control group, the ‘‘screened
controls’’, were a cohort of Australians of European descent
involved in other genetic studies who were examined for eye
disease and found to be unaffected by experienced ophthal-
mologists at the Flinders Eye Clinic (n ¼ 230). While these
individuals had no clinical evidence of keratoconus, the
majority of these individuals had advanced glaucoma (n ¼
195). The remaining individuals either had no evidence of eye
disease (n ¼ 22) or were unaffected individuals from families
with congenital cataract (n ¼ 9) and nanophthalmos (n¼ 4).
Whole Exome Sequencing
Whole exome sequencing (WES) data were available for 99
keratoconus cases, the screened control cohort (n¼ 230) and
the population control cohort (n ¼ 346). WES for the
keratoconus patients and the screened control cohort was
conducted by Macrogen, Inc., using the SureSelect Human All
Exon V4 enrichment kit (Agilent Technologies, Inc., Santa
Clara, CA, USA) with paired end sequencing on a HiSeq 2000
(Illumina, San Diego, CA, USA). Raw reads were aligned to the
hg19 reference genome with BWA-MEM using the Churchill
Pipeline19 and variants were joint-called with SAMtools and
BCFtools (versions 1.3.1).20 The population control cohort was
sequenced at the University of Queensland Centre for Clinical
Genomics using the TruSeq Exome Enrichment (Illumina) on
an Illumina HiSeq 2000. Raw reads were aligned to the
reference genome (hg19) using novoalign (version .02.08), and
GATK21 (version 3.2-2) was used for variant calling and quality
score calibration according to GATK’s ‘‘Best Practices Guide-
lines’’.22,23 To assess coverage across ZNF469 in the WES data
(cases and the two control groups), the mean read depth for
each variant position was determined using VCFtools24 and
graphed using custom R25 scripts using the R packages
ggplot226 and cowplot.27 For each cohort, regions with a
mean depth of <10 were excluded from analyses. These
regions were different for the two control cohorts. Variants
were only included in analyses if a sequencing depth of ‡10
and a quality score ‡20 was obtained.
Targeted Gene Screen in Additional Cases
ZNF469was screened in a total 341 cases as part of a candidate
gene screen using the HaloPlex Target Enrichment System
(Agilent Technologies, Inc.) with a custom designed probe
panel on pooled DNA samples (Supplementary Table S1). A
brief summary of the design is presented in Supplementary
Figure S1. DNA pools containing equimolar DNA samples from
eight keratoconus patients were prepared as published
previously.28 Each DNA pool was indexed with a unique
indexing primer cassette, allowing for multiplexed sequencing.
Sequencing was conducted in batches of 11 DNA pools on the
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MiSeq platform (Illumina) using a MiSeq V2 Reagent kit (300
cycles) with paired-end reads. SureCall (Agilent Technologies,
Inc.) was used for sequencing analysis using standard trimmer
parameters, the BWA-MEM algorithm to align reads and the
SNPPET SNP Caller (part of SureCall) to call variants. Variants
were called if a minimum read depth of 10 and quality score of
20 was reached. As variants were called from pooled DNA
samples, it was expected that if a single alternate allele was
present it would be observed on 6.25% of the reads mapping to
that position. To account for this, the minimum allele
frequency for heterozygous variants was set to 0.035 and the
threshold for indel calling was ‡ 0.04. Suspected artefacts and
real variants were selected for validation by direct sequencing
in all individuals included in the DNA pool, to identify
thresholds for the inclusion of variants. In addition, 55 cases
included in this candidate gene screen were included in the
WES; providing additional cross-validation between the two
sequencing strategies. However, variants from these samples
were only counted in the analyses once. An in-depth
description of the validation of variant calls from the pooled
gene screen and the development of thresholds for variant
inclusion is available in the Supplementary Materials.
Variant Validation by Direct Sequencing
To validate variants called in the case data set, primers were
designed using Primer3Plus.29 DNA samples were ampliﬁed
with either GoTaq (Promega, Madison, WI, USA), HotStar Taq
Kit (Qiagen), or MyTaq HS Mix (Bioline, London, UK) and
puriﬁed using Agencourt AMPure XP (Beckman Coulter, Brea,
CA, USA) according to the manufacturer’s instructions. Puriﬁed
amplicons were sequenced using the BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA,
USA) on either an ABI 310 Genetic Analyzer or an ABI 3500
(Applied Biosystems). DNA sequences were aligned to the
human reference genome (hg19), and the chromatograms
were manually inspected at the position of each variant using
Sequencher 4.10.1 (Gene Codes Corporation, Ann Arbor, MI,
USA).
Variant Filtering Strategies
While it has recently been suggested that ZNF469 is a single-
exon gene,30 the capture methods in this study were all
designed under the assumption that ZNF469 has two exons
with a short 84bp intron. Therefore, only exonic variants were
included in analyses. To ensure high quality sequence data and
robust comparisons, only regions with sufﬁcient coverage
across the relevant data sets were included in each compar-
ison. ANNOVAR31 was used to annotate variants with the
minor allele frequency (MAF) of the non-Finnish European
population in the Exome Aggregation Consortium database32
(ExAC NFE), as well as the predicted pathogenicity of the
variants using Sorting Tolerant from Intolerant (SIFT)33 and the
HumDIV algorithm from Polymorphism Phenotyping v2 (Poly-
Phen2).34 To make our results comparable to previous studies,
two ﬁltering strategies were used to deﬁne rare and very rare
potentially pathogenic variants. Filtering strategy 1 included
nonsynonymous variants with a MAF < 0.01 (rare) with a
damaging or probably/possibly damaging prediction by SIFT
and/or PolyPhen2. As SIFT and PolyPhen2 do not assess
insertions/deletions (indels), all indels with a MAF <1% were
included in ﬁltering strategy 1. Filtering strategy 2 was identical
to ﬁltering strategy 1, except variants were required to have a
MAF < 0.001 (very rare).
Statistical Analyses
For both ﬁltering strategies, the number of alternate alleles was
compared between cases and the two control data sets
separately using v2 or Fisher’s exact tests, where appropriate.
The odds ratio (OR) and 95% conﬁdence interval (95% CI)
were calculated. In addition, the Sequence Kernel Association
Test (SKAT)35 was used to assess if potentially pathogenic
variants were enriched in the case WES data compared to the
two control cohorts. Using the two control cohorts as a
separate comparison, SKATBinary was run using the quantile
adjusted moment matching (QA) method and the default
weight parameter, Beta (1,25). This weighting applies strong
weights to rare variants, nonzero weighting to uncommon
variants (MAF 0.01–0.05), and almost zero weights to common
variants.35
Genetic Power Calculations
Power calculations were conducted using the case-control for
discrete traits module of the genetic power calculator (http://
zzz.bwh.harvard.edu/gpc/).36 These calculations assumed an
additive module where the prevalence of keratoconus was
0.00067 (1 in 1500) and D’ prime was equal to 1. The high-risk
allele frequency was set for each ﬁltering strategy separately,
using the frequency of variants identiﬁed in the screened
controls.
Variant Visualization
Variants included in ﬁltering strategy 1 were plotted as a bar plot
for each group using custom R25 scripts and the R package
ggplot2.26 Each variant was plotted along the x-axis according to
its genomic position, and the frequency of the variant in the
study group was indicated by the height of the bar. Indels were
plotted according to the position of the ﬁrst affected base. To
indicate the conservation of each variant position, the bars were
colored using a color gradient corresponding to the 100-way
vertebrate PhastCons37,38 score as available from the University
of California Santa Cruz (UCSC) genome browser.39 The plots for
each group were aligned to a schematic of ZNF469 using the R
package cowplot,27 to allow for comparison of the variants
across the gene. The position of the zinc ﬁnger motifs was
plotted onto the gene schematic based on the positions
obtained from UniProt40 (entry Q96JG9).
RESULTS
A total of 385 cases, 346 population controls, and 230 screened
controls were included in analyses. Demographic details are
provided in Table 1.
TABLE 1. Demographics of the Keratoconus Cases and Control Groups at the Time of Examination
Cohort No. of Individuals Mean Age in Years (Range) % Female Disease Status
Cases 385 45.2 (14–85) 44.2 Affected
Population controls* 346 69.5 (46–86) 100 Unscreened
Screened controls 230 68.6 (8–92) 56.5 Unaffected
* The demographics were collected at the time of bone densitometry for this group.
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As we applied a stringent coverage ﬁlter to all sequence data
sets, regions containing the majority of the ﬁrst exon, the
beginning of exon two, and the regions encoding the zinc
ﬁnger domains were excluded from analyses that compared the
cases to the population control cohort (Fig. 1). Therefore,
comparisons using the population controls included a total of
6700 bases across ZNF469 with high quality sequence data,
which corresponds to 56.5% of the coding regions. In contrast,
a total of 11,448 bases (96.5% of the coding regions) obtained
sufﬁcient coverage across the gene in both the cases and
screened controls. For comparisons using the screened
controls, only two small regions (85 bp and 279 bp) either
side of the intron were excluded from analysis due to poor
coverage (Fig. 1). By removing these regions from analysis, the
single region that did not meet the minimum depth threshold
in the pooled gene screen data was also excluded. A summary
of the coverage metrics for the gene screen data set is
presented in Supplementary Table S2.
Across all cohorts, 49 variants (46 single nucleotide variants
and three small deletions) fulﬁlled the criteria for rare
potentially pathogenic variants in ﬁltering strategy 1 (Table
2). Of these, 19 variants were observed in cases only, while 17
were unique to the control cohorts and the remaining 13 were
in both cases and controls. Eleven variants had been observed
in previous studies in either cases or controls, with an
additional two variants that are not identical, but occur at
the same amino acid as a previously reported variant. A total of
33 rare potentially pathogenic variants were observed 73 times
in cases and 23 variants were called 48 times in the screened
controls, which was not signiﬁcantly different (P¼ 0.66; Table
3). When considering the comparison between the cases and
the population controls, 17 variants were identiﬁed 31 times in
cases and 10 variants were observed 22 times in the controls,
which was not signiﬁcantly different between groups (P ¼
0.47; Table 3).
Filtering strategy 2 identiﬁed 33 very rare potentially
pathogenic variants across all cohorts (Table 2). Sixteen of
these variants were unique to keratoconus patients and two,
p.(C1693F) and p.(P2548L), were identiﬁed in two cases each.
Fifteen variants were observed in the control cohorts only,
including p.(P3372L), which was identiﬁed in two individuals.
Two variants, p.(P626_G628del) and p.(E3781K), were iden-
tiﬁed in both a case and a control. All other variants were
observed in a single individual. Two variants, p.(S2242Y) and
p.(P3372L), were previously observed in the study by Lechner
et al.17 and p.(E935G) is located at the same amino acid as a
variant identiﬁed in the study by Davidson and colleagues.15 In
total, 18 variants were identiﬁed 20 times in cases and 12
variants were observed 13 times in the screened controls. For
the population control comparison, 10 variants were observed
in 12 cases and ﬁve variants were identiﬁed in the controls.
Similar to the results for rare variants, very rare variants were
not enriched in cases compared to either the screened controls
(P ¼ 0.96) or the population controls (P ¼ 0.15; Table 3).
Furthermore, the SKAT analyses demonstrated no signiﬁcant
enrichment of variants predicted to be damaging (P ¼ 0.06;
Table 4).
For the power calculations, the high-risk allele frequency
was assumed to be the frequency of variants identiﬁed by the
ﬁltering strategies in the 230 screened controls. This was
determined to be 0.104 (48/460) for strategy 1 and 0.028 (13/
460) for strategy 2. Using these values, our study had 80%
power to detect a relative risk of 1.5 and 2.0, respectively.
For each cohort, the allele frequencies were plotted against
the variant position and mapped to a schematic of the gene
(Fig. 2). The ﬁrst exon showed a similar pattern of variation
FIGURE 1. Sequencing coverage in the WES data sets. (A) Coverage across ZNF469 in each data set, based on the mean read depth at variant
positions. The horizontal dashed line indicates the minimum depth threshold accepted (10 reads). Regions where the mean read depth in the
population controls was below this threshold are shaded light gray and were excluded from analyses in which these controls were included.
Regions with insufﬁcient coverage in all cohorts are shaded darker gray. (B) A schematic of ZNF469 where dark gray boxes indicate the position of
the zinc ﬁnger motifs and the small intron is indicated by the horizontal line.
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between the cases and screened controls (Fig. 2). Due to
insufﬁcient coverage of this region in the population controls,
variation in this group could not be assessed. Of the 13 variants
in cases in exon 1, two variants, p.(S242I) and p.(R503W),
were located at highly conserved nucleotides (PhastCons score
>0.99) and p.(E679K) was at a relatively conserved position
with a PhastCons score of 0.655. The p.(R503W) variant was
observed in a single case (frequency of 0.0013), whereas both
p.(S242I) and p.(E679K) were identiﬁed in one case and one
screened control (frequency of 0.0022).
TABLE 2. Variants Included in Analysis Under Filtering Strategy 1 (Rare Potentially Pathogenic Variants) Including the Position, Nucleotide and
Protein Changes, Population Frequency, the 100-Way Vertebrate PhastCons Score, Cohort Frequency (Freq) and Allele Count (AC)
Position (hg19)
Nucleotide
Change
Protein
Change
MAF in
ExAC NFE
PhastCons
Score
Case
Freq (AC)
Screened
Controls
Freq (AC)
Population
Controls
Freq (AC)
Included
in FS2
Observed
in Other
Published
Studies
chr16:88494603 c.725G>T p.(S242I) 0.0024 0.9930 0.0013 (1) 0.0022 (1) * N
chr16:88494809 c.931G>A p.(G311R) 0.0000 0.0000 0.0013 (1) 0.0000 * Y
chr16:88495361 c.1483C>T p.(P495S) 0.0015 0.0040 0.0013 (1) 0.0022 (1) * N
chr16:88495385 c.1507C>T p.(R503W) 0.0003 0.9980 0.0013 (1) 0.0000 * Y
chr16:88495400 c.1522G>A p.(A508T) 0.0003 0.0000 0.0013 (1) 0.0000 * Y
chr16:88495443 c.1565G>T p.(G522V) 0.0000 0.0010 0.0000 0.0022 (1) * Y
chr16:88495461 c.1583C>G p.(P528R) 0.0000 0.0000 0.0013 (1) 0.0000 * Y
chr16:88495487 c.1609G>A p.(V537M) 0.0010 0.0000 0.0038 (3) 0.0022 (1) * N 17
chr16:88495568 c.1690G>C p.(G564R) 0.0002 0.3100 0.0013 (1) 0.0000 * Y
chr16:88495575 c.1697C>T p.(A566V) 0.0098 0.0000 0.0115 (9) 0.0283 (13) * N 15,18
chr16:88495753-
88495761
c.1875_1883del p.(P626_P628del) 0.0000 0.0000 0.0013 (1) 0.0022 (1) * Y
chr16:88495872 c.1994C>T p.(P665L) 0.0062 0.0420 0.0102 (8) 0.0109 (5) * N 17
chr16:88495913 c.2035G>A p.(E679K) 0.0064 0.6550 0.0013 (1) 0.0022 (1) * N 15
chr16:88496430 c.2552T>C p.(M851T) 0.0000 1.0000 0.0000 0.0022 (1) * Y
chr16:88496682 c.2804A>G p.(E935G) 0.0000 0.0040 0.0013 (1) 0.0000 * Y 15†
chr16:88497443 c.3481C>A p.(P1161T) 0.0000 0.0000 0.0000 0.0022 (1) * Y
chr16:88497830 c.3868G>A p.(D1290N) 0.0000 0.0020 0.0000 0.0022 (1) * Y
chr16:88498350 c.4388C>T p.(T1463M) 0.0035 0.0020 0.0000 0.0022 (1) 0.0058 (4) N 17
chr16:88499040 c.5078G>T p.(C1693F) 0.0002 0.0000 0.0026 (2) 0.0000 0.0000 Y
chr16:88500687 c.6725C>A p.(S2242Y) 0.0001 0.0000 0.0000 0.0000 0.0014 (1) Y 17
chr16:88500713 c.6751C>T p.(P2251S) 0.0000 0.0040 0.0000 0.0022 (1) 0.0000 Y
chr16:88500822 c.6860C>G p.(P2287R) 0.0002 0.0010 0.0013 (1) 0.0000 0.0000 Y
chr16:88500957 c.6995C>T p.(P2332L) 0.0033 0.0000 0.0064 (5) 0.0000 0.0000 N
chr16:88501145 c.7183C>A p.(P2395T) 0.0044 0.0000 0.0038 (3) 0.0022 (1) 0.0000 N
chr16:88501224 c.7262G>A p.(R2421H) 0.0002 0.0000 0.0013 (1) 0.0000 0.0000 Y
chr16:88501344 c.7382G>A p.(R2461Q) 0.0002 1.0000 0.0000 0.0022 (1) * Y
chr16:88501431 c.7469C>A p.(P2490H) 0.0034 0.0000 0.0013 (1) 0.0000 0.0000 N 17
chr16:88501605 c.7643C>T p.(P2548L) 0.0000 0.0000 0.0026 (2) 0.0000 0.0000 Y
chr16:88501749 c.7787C>T p.(P2596L) 0.0010 0.0000 0.0000 0.0000 0.0058 (4) N
chr16:88501995 c.8033C>T p.(A2678V) 0.0000 0.0000 0.0013 (1) 0.0000 0.0000 Y
chr16:88502222 c.8260C>T p.(H2754Y) 0.0009 0.0000 0.0000 0.0022 (1) 0.0000 Y
chr16:88502276 c.8314C>A p.(L2772M) 0.0000 0.0000 0.0000 0.0000 0.0014 (1) Y
chr16:88502304 c.8342C>T p.(P2781L) 0.0000 0.0000 0.0013 (1) 0.0000 0.0000 Y
chr16:88502583 c.8621C>T p.(T2874M) 0.0011 0.0000 0.0026 (2) 0.0000 0.0000 N
chr16:88502666 c.8704G>T p.(D2902Y) 0.0010 0.9700 0.0038 (3) 0.0000 0.0029 (2) N 17
chr16:88502723 c.8761C>G p.(P2921A) 0.0000 0.0030 0.0000 0.0000 0.0014 (1) Y
chr16:88502862 c.8900C>T p.(A2967V) 0.0000 0.0030 0.0013 (1) 0.0000 0.0000 Y
chr16:88502972-
88502986
c.9010_9024del p.(L3004_T3008del) 0.0043 0.0000 0.0051 (4) 0.0022 (1) 0.0014 (1) N 15†,17†
chr16:88503039 c.9077A>C p.(E3026A) 0.0000 0.9690 0.0013 (1) 0.0000 0.0000 Y
chr16:88503372 c.9410A>G p.(E3137G) 0.0000 1.0000 0.0013 (1) 0.0000 * Y
chr16:88503596 c.9634A>T p.(R3212W) 0.0000 0.0000 0.0000 0.0022 (1) * Y
chr16:88503838 c.9876G>T p.(E3292D) 0.0000 0.0010 0.0000 0.0022 (1) * Y
chr16:88504077 c.10115C>T p.(P3372L) 0.0000 1.0000 0.0000 0.0043 (2) * Y 17
chr16:88504239 c.10277G>A p.(R3426Q) 0.0078 0.3970 0.0140 (11) 0.0196 (9) * N 15,17
chr16:88504492 c.10530delC p.(I3510fs) 0.0000 0.0000 0.0000 0.0000 0.0014 (1) Y
chr16:88504766 c.10804C>T p.(R3602C) 0.0031 0.0000 0.0013 (1) 0.0022 (1) 0.0087 (6) N 17
chr16:88504775 c.10813T>G p.(C3605G) 0.0000 0.0000 0.0000 0.0000 0.0014 (1) Y
chr16:88505303 c.11341G>A p.(E3781K) 0.0005 1.0000 0.0013 (1) 0.0022 (1) 0.0000 Y
chr16:88505654 c.11692G>A p.(E3898K) 0.0000 1.0000 0.0013 (1) 0.0000 0.0000 Y
FS2, Filtering Strategy 2 (very rare potentially pathogenic variants).
* Variant with insufﬁcient coverage.
† Variant previously reported at the same amino acid, but a different nucleotide.
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Few variants were located in the proximal region of exon 2,
with only one variant identiﬁed in cases. In contrast, a cluster
of variants was observed in cases in the distal half of exon 2
(Fig. 2). Speciﬁcally, variants were observed in the region
spanning just proximal of the ﬁrst zinc ﬁnger motif to midway
between the second and third zinc ﬁnger motif. Noticeably
fewer variants were observed in the control cohorts within this
region (Fig. 2). Three variants identiﬁed in cases within this
cluster, p.(D2902Y), p.(E3026A) and p.(E3137G), were highly
conserved (PhastCons scores > 0.96). The p.(D2902Y) variant
was present at a similar frequency in cases (0.0038) and the
population controls (0.0029), while p.(E3026A) and
p.(E3137G) were present in one case and absent in controls.
Two additional variants, p.(E3781K) and p.(E3898K), were
identiﬁed at highly conserved residues at the very distal end of
exon two (PhastCons score ¼ 1). These variants were both
identiﬁed a single case and neither of these variants were
observed in the population controls despite good coverage in
this region; however, the p.(E3781K) variant was observed in a
one screened control.
Across ZNF469, three variants—p.(A566V), p.(P665L), and
p.(R3426Q)—were identiﬁed at a frequency >0.01 in both the
cases and the screened control cohort, despite a MAF < 0.01 in
the public ExAC NFE database. The frequency of these variants
could not be assessed in the population controls due to
insufﬁcient coverage; however, all three variants were ob-
served in cases at a similar or lower frequency than the
screened controls.
DISCUSSION
In our cohort of Australians of European descent, the overall
frequency of rare potentially pathogenic variants in ZNF469
was not different between keratoconus cases and two
independent control cohorts using two ﬁltering strategies.
Despite a much larger cohort than the earlier studies, our
ﬁndings were unable to replicate previous reports that show
an association of potentially pathogenic variants in ZNF469
and keratoconus development with relative risks of up to
12.17,18 Our study had 80% power to detect a relative risk of
1.5 for rare potentially pathogenic variants, and 2.0 for very
rare potentially pathogenic variants, commensurate with
expected effect sizes for rare variants in a complex disease.
In our study, we show that the reported large effect sizes do
not exist when the whole gene is considered in both cases and
controls and therefore if this gene is contributing to
keratoconus risk, then effect sizes are likely to be quite small.
The main ﬁnding of this paper is that the reported large effects
of rare variants are likely spurious and are brought about by
biased reporting of variants detected in fully sequenced cases
not being present in controls who are not fully sequenced or
due to the exclusion of variants that are observed in control
individuals. Our work shows that controls have just as many
variants meeting the potentially pathogenic criteria as kerato-
conus patients.
Due to the size of our study, we were also able to map the
location of the rare potentially pathogenic variants identiﬁed in
all three cohorts and show that they span the whole gene, with
particular aggregation in the ﬁrst exon and the distal half of the
second exon. Only eight variants observed in cases were
located at highly conserved nucleotides. Four of these variants
were identiﬁed at similar frequencies in both cases and
controls and four were only observed in a single case. While
it is possible that these rare variants may contribute to
keratoconus susceptibility in these few cases, on the whole,
the evidence indicates that rare, potentially pathogenic
variants in ZNF469 do not make a substantial contribution to
keratoconus risk. This ﬁnding is consistent with the work by
Davidson and colleagues,15 which showed that uncommon
variants (MAF <0.025) did not segregate with disease in
families with keratoconus and therefore, at least in isolation, do
not contribute to keratoconus susceptibility. Furthermore, the
results of the Polish study16 indicate that potentially patho-
genic variants are not enriched in keratoconus, and that
ZNF469 is highly allelic in the general population.
The ﬁrst reports to assess coding variants in ZNF469 were
published by Lechner et al.17 and Vincent et al.18 Subsequent
studies, including this one, have used similar ﬁltering strategies
to allow for direct comparison. Our ﬁltering strategy 1 was
based on the criteria used by Vincent et al.,18 while ﬁltering
strategy 2 was based on the method used by Lechner et al.17
with two key changes. Firstly, Lechner et al.17 removed any
variants from analysis that were present in both their cases and
controls. We did not do this as keratoconus is a complex
disease and therefore it is likely (and expected) that unaffected
individuals will carry risk associated variants without ever
TABLE 3. Association Analyses Using v2 or Fisher’s Exact Test Under Each Filtering Strategy
Cohort
Alternate
Alleles
Wild Type
Alleles
Alternate Allele
Frequency P Value OR [95% CI]
Filtering strategy 1
Comparison 1 Cases 73 697 0.09
Screened controls 48 412 0.1 0.66 0.90 [0.60–1.34]
Comparison 2 Cases 31 739 0.04
Population controls 22 670 0.03 0.47 1.28 [0.71–2.31]
Filtering strategy 2
Comparison 1 Cases 20 750 0.03
Screened controls 13 447 0.03 0.96 0.92 [0.43–1.97]
Comparison 2 Cases 12 758 0.02
Population controls 5 687 0.01 0.15* 2.18 [0.71–7.11]
For each cohort, the number of alternate and wild type alleles and the frequency of the alternate allele are reported. For each comparison, the P
value, the OR, and the 95% CI are shown.
* Fisher’s exact P value.
TABLE 4. The Results of the SKAT Analyses
Comparison
Alternate
Alleles MAC
Carrier
Individuals
P
Value
Cases vs. screened controls 38 415 271 0.06
Cases vs. population controls 20 473 337 0.06
For each comparison, the number of alternate alleles included in
the analysis, the total minor allele count (MAC), the number of
individuals with these variants (carrier individuals), and the P value.
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developing disease. Secondly, Lechner et al.17 only used SIFT
predictions to classify variants as potentially pathogenic. SIFT
uses protein conservation to calculate pathogenicity by
comparing a query sequence to similar sequences with similar
function.33 As ZNF469 is a highly variable gene with low
conservation in lower mammals and vertbrates,41 SIFT may
misclassify deleterious variants in regions of low conservation.
In contrast, PolyPhen2 uses the properties of the substituted
amino acids and the proximity to functional domains or
structural features, as well as protein conservation to predict
pathogenicity.34 As the structure and function of the ZNF469
protein remains largely unknown,41 PolyPhen2 is likely to
better assess regions with poor conservation, particularly the
regions that ﬂank the zinc ﬁnger domains. Therefore, our study
used both SIFT and PolyPhen2 to better capture the
pathogenicity of nonsynonymous variants identiﬁed in
ZNF469. Our study used these robust and complementary
methods to replicate the analytical strategies of the previous
studies; however, our ﬁndings do not support any enrichment
of rare potentially pathogenic variants in ZNF469 in keratoco-
nus cases.
We assessed rare potentially pathogenic variants in ZNF469
in the largest cohort of keratoconus patients to date by
combining WES data and sequencing data from a targeted gene
screen using pooled DNA samples. Following extensive
validation experiments, we demonstrated a high level of
consistency of variant calls for individuals sequenced by both
methods, validating the utility of pooling DNA samples to
maximize cost-effectiveness. Furthermore, these validation
experiments were used to develop stringent thresholds that
were then applied to all data to ensure only high quality
variants were included in analyses. While variants were not
assessed for validation in the control cohorts, the inclusion of
additional control variants that were ﬁltered out due to these
stringent thresholds would only strengthen our ﬁndings of no
association. Furthermore, to minimize bias due to poor
coverage of ZNF469 in the population controls, a strict
coverage threshold was applied such that only regions with
sufﬁcient coverage were assessed when comparing to this
control group. While this may have resulted in the exclusion of
important variants, the vast majority of these regions had
sufﬁcient coverage in the screened controls and therefore were
still assessed.
As suggested by Davidson et al.,15 it is likely that variation in
ZNF469 is underrepresented in public databases as a result of
the poor coverage of the gene by the older WES capture
techniques. According to the ExAC Browser, the mean
coverage for ZNF469 (ENSG00000225614) is 7.3 reads and
the proportion of individuals with at least 103 coverage is less
than 20%. Our experience with the poor coverage of ZNF469
FIGURE 2. Summary of identiﬁed variants. (A) Schematic of ZNF469 with zinc ﬁnger motifs shaded dark gray, (B–D) bar plots indicating the
position and alternate allele frequency (AAF) of rare potentially pathogenic variants in 784 case alleles, 460 screened control alleles, and 692
population control alleles, respectively. The bars are colored according to the 100-way vertebrate PhastCons Score for the corresponding position,
where dark blue is a score of 0 and red is a score of 1. Light gray shading on the plots for the control cohorts indicate regions with insufﬁcient
coverage for variant calling that were excluded from analysis when using these data. The gene schematic and all graphs are aligned vertically to
share the same x-axis to allow for comparison.
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in the population control data set, as well as the occurrence of
three variants that were identiﬁed in our cases and screened
controls at a frequency of > 0.01, despite being annotated with
a MAF < 0.01 in the ExAC NFE database, supports this. As one
might expect, these variants could not be assessed in the
population controls due to insufﬁcient coverage. All three of
these variants were located at relatively nonconserved
nucleotides (PhastCons scores <0.4). Two of these variants,
p.(P665L) and p.(R3426Q), were observed at similar frequen-
cies in both our cases and controls and therefore were
hypothesized to be benign polymorphisms. These variants
were similarly classiﬁed in the study by Lechner and
colleagues, but were not identiﬁed in other reports.15–18 The
third variant, p.(A566V), was identiﬁed at more than twice the
frequency in the screened controls (0.028) than the cases
(0.012). Vincent et al.18 reported this variant in one Indian and
two Caucasian keratoconus cases, while Davidson et al.15
identiﬁed the variant in two cases and two unaffected
individuals from two separate consanguineous families of
Middle Eastern origin. In addition, the work by Lechner et al.17
excluded the variant from analysis due to a MAF > 0.01 in their
control cohort. As our screened control cohort largely consists
of advanced glaucoma patients, it is possible that these variants
may be involved in glaucoma susceptibility. However, in the
original GWAS that identiﬁed the association between the SNP
upstream of ZNF469 (rs9938149) and CCT as well as
keratoconus, glaucoma cases were also assessed and no
association was identiﬁed.13 Therefore, it is more likely that
these variants are benign, uncommon polymorphisms.
CONCLUSIONS
Our study included more keratoconus cases than the total
number previously studied and demonstrated no signiﬁcant
difference in the overall frequency of potentially pathogenic
variants in ZNF469 compared to controls. In addition, our
ﬁndings conﬁrm the highly variable nature of ZNF469 and the
poor capture of the gene by previous generation WES capture
methods, which is likely to have resulted in underestimates of
alternate allele frequencies in public databases. Overall, this
study indicates that rare potentially pathogenic variants are
unlikely to contribute to keratoconus pathogenesis and do not
account for the association at the distant upstream SNP,
rs9938149.
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